Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

Study summary

RATIONALE: Measuring how well the lungs work in patients with cancer may help doctors predict how patients will respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying lung function testing in patients with locally advanced or metastatic solid tumors.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedpulmonary function testing

The study team can explain what participation involves.

Who it may be forLocally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 8, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Barbara Ann Karmanos Cancer Institute

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Not applicable
Sponsor: Barbara Ann Karmanos Cancer Institute
Interventions being studied: Procedure: pulmonary function testing

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Locally advanced→Metastatic or stage IV→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
Locally advanced or metastatic disease
Disease progressed on or after standard therapy OR there is no standard therapy for the malignancy
Standard therapy is defined as first- or second-line therapy that has been shown to provide clinical benefit
Life-long non-smoker
No lung metastasis and/or pleural effusion causing signs or symptoms that impact patient performance status PATIENT CHARACTERISTICS:
ECOG performance status 0-1
Body mass index ≤ 35
No concurrent uncontrolled illness including, but not limited to, the following:
Ongoing or active infection
Symptomatic congestive heart failure
Unstable angina pectoris
Ventricular arrhythmia
Psychiatric illness or social situation that would limit compliance with study requirements
No uncontrolled chest or abdominal pain
No oral or facial pain exacerbated by an oral device
No stress incontinence
No COPD, interstitial lung disease, pulmonary embolism, or hemorrhage within the past 6 months
No history of pulmonary fibrosis or pulmonary hypertension
No oxygen requirement at baseline
No asthma
No occupational lung disease, including, but not limited to, asbestos exposure
No polycythemia
No history of connective tissue disease PRIOR CONCURRENT THERAPY:
No prior radiotherapy to the lung
At least 6 months since prior lung surgery
No prior amiodarone hydrochloride
No prior high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation
No concurrent combination antiretroviral therapy for HIV-positive patients

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Barbara Ann Karmanos Cancer InstituteDetroit, Michigan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 8, 2021. Always confirm current availability with the study team.

View original record ↗